Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis.
Anogenital warts (AGWs, condylomata acuminata) are among the most common STIs and may severely impact quality of life (QoL). Available treatment options are characterised by a high proportion of non-responders and recurrences.



To systematically review and meta-analyse the available evidence from randomised controlled trials (RCTs) on topical treatments for AGWs considering short-term and long-term efficacy, effects on QoL and adverse events (AE).



A comprehensive literature search was performed in Cochrane Central Register of Controlled Trials, Embase and MEDLINE. Included studies were evaluated with the Cochrane Collaboration's risk of bias tool. The confidence in the pooled effect estimates was evaluated according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and categorised as 'very low', 'low', 'moderate' or 'high'.



Eighteen RCTs met the inclusion criteria. Regarding complete clearance (CC), imiquimod 3.75% and 5% cream, podophyllotoxin 0.5% solution and gel and polyphenon E 10% and 15% ointment were superior to placebo. Although more local AE and pain occurred in the actively treated groups, differences regarding dropouts due to AE were not statistically significant. For podophyllotoxin 0.15% cream, no placebo-controlled trials were available; however, in an active-controlled trial, it was inferior to podophyllotoxin 0.5% solution with respect to CC. No significant differences were detected between imiquimod 5% cream and podophyllotoxin 0.5% solution and between polyphenon E 10% and 15% ointment. No data on the influence on health-related QoL were available.



Our confidence in the pooled estimates (GRADE quality of the evidence) ranged from very low to high. Apart from the given results, other aspects such as availability, costs or patient preference have to be considered when making a treatment choice. Due to the limited number of direct comparisons, conclusions on the relative efficacy of the different treatment options are restricted.
Division of Evidence-based Medicine, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Ricardo Niklas
RN
Werner
Division of Evidence-based Medicine, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Lukas
L
Westfechtel
Division of Evidence-based Medicine, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Corinna
C
Dressler
Division of Evidence-based Medicine, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Alexander
A
Nast
D000287:Administration, Topical; D001004:Anus Diseases / Q000188:drug therapy* / Q000821:virology; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007121:Immunocompetence; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D027383:Papillomaviridae / Q000187:drug effects / Q000302:isolation & purification; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012646:Self Administration
D007369:Interferon Inducers
ANOGENITAL CONDITIONS; CONDYLOMA; HPV; META-ANALYSIS; SYSTEMATIC REVIEWS